CVKD (Cadrenal Therapeutics) Inventories, Work In Process: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CVKD Cadrenal Therapeutics Inc CVKD
26 GF Score
Price $2.03
! 2 Warning Signs
View Full Analysis

What is Cadrenal Therapeutics Inventories, Work In Process?

Cadrenal Therapeutics CVKD +2.01% 26 Inventories, Work In Process is $0.00 Mil as of Mar. 2026. GuruFocus rates CVKD with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Cadrenal Therapeutics's work in process for the quarter that ended in Mar. 2026 was $0.00 Mil.

Cadrenal Therapeutics Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Cadrenal Therapeutics's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cadrenal Therapeutics Inventories, Work In Process Chart

Cadrenal Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
0.00 0.00 0.00 0.00

Cadrenal Therapeutics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CVKD
26GF Score
Cadrenal Therapeutics Inc CVKD
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cadrenal Therapeutics Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of $0.00 Mil mean?
Cadrenal Therapeutics (CVKD) has a Inventories, Work In Process of $0.00 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Cadrenal Therapeutics and its competitors.
Is Cadrenal Therapeutics' Inventories, Work In Process too high?
Cadrenal Therapeutics' current Inventories, Work In Process is $0.00 Mil. Overall, Cadrenal Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Cadrenal Therapeutics' Inventories, Work In Process compare to RVPH and IMNN?
Cadrenal Therapeutics' Inventories, Work In Process of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Cadrenal Therapeutics and its competitors. Cadrenal Therapeutics's current Inventories, Work In Process is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cadrenal Therapeutics stock overvalued right now?
Cadrenal Therapeutics (CVKD) has a current Inventories, Work In Process of $0.00 Mil. The current Inventories, Work In Process is $0.00 Mil. Cadrenal Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Cadrenal Therapeutics (CVKD), the current Inventories, Work In Process is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cadrenal Therapeutics Business Description

Address 822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
26GF Score

Get the complete analysis for CVKD

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.03
Price